INBRX-103 is a mAb that targets cluster of differentiation 47, or CD47, which blocks a tumor protective pathway. CD47 is co-opted by many tumor types to protect tumor cells from being engulfed by macrophages. Despite promising activity, anti-CD47 antibody therapeutics are known to cause anemia and infusion site reactions. To our knowledge, INBRX-103 was the first anti-CD47 antibody observed preclinically to block the interaction of CD47 and signal regulatory protein alpha, or SIRPa, without causing agglutination, or clumping, of red blood cells. In preclinical studies, administration of INBRX-103 was not associated with red blood cell or platelet depletion and exhibited a favorable toxicity profile in primates. We believe this lack of red blood cell agglutination could result in a differentiated clinical profile with a lower probability for anemia and infusion site reactions. We believe this program has broad therapeutic potential in combination with tumor-targeting antibodies that can engage activating Fc receptors. We licensed worldwide development and commercialization rights to INBRX-103 to Celgene, which refers to the therapeutic candidate as CC-90002, in 2013, and Celgene is currently conducting a Phase 1 clinical trial of this therapeutic candidate in combination with rituximab.